Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cafusotide
- Development stage
- Phase 1
- Lead developer
- Hengrui Therapeutics
- Modality
- Peptides
- Administration
- Intravenous
01
Overview
Cafusotide (SHR-1103) is a synthetic peptide developed by Jiangsu Hengrui Medicine for the treatment of advanced solid tumors. It acts as an antagonist of the urokinase-type plasminogen activator receptor (uPAR, also known as CD87). By competitively binding to uPAR, cafusotide prevents the interaction between uPAR and its ligand, urokinase-type plasminogen activator (uPA). This interaction is a critical driver of extracellular matrix degradation, tumor cell invasion, and metastasis. Cafusotide was evaluated in Phase 1 clinical trials in China to assess its safety, pharmacokinetics, and preliminary antitumor activity in patients with advanced malignancies.
- Other names
- cafusotide hydrochloride
02
Targets
PLAUR (Urokinase plasminogen activator receptor)
Beyond the preview
Go deeper on cafusotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cafusotide.